[Pharmacokinetic and clinical studies of XXXX in perinatal period].

@entity1 @entity281 @entity8353 @entity5505
Pharmacokinetic studies and clinical evaluations of @entity5505 ( @entity8353 ) were carried out in perinatal mothers and @entity1 , and following results were obtained. The @entity8353 was promptly absorbed after intravenous injection or intravenous drip infusion in pregnant @entity1 , producing dose-related peak serum levels. Placental transference to the fetus was good. After intravenous injection or intravenous drip infusion of 1.0-2.0 g of @entity8353 , drug concentration in umbilical serum and amniotic fluid exceeded MICs of @entity8353 against main pathogenic organisms. Levels of @entity8353 in umbilical serum ranged 0.2-15.6 micrograms/ml after 1.0 g intravenous injection or intravenous drip infusion, and 0.7-27.2 micrograms/ml after 2.0 g intravenous injection, and those in amniotic fluid were 1.4-21.3 micrograms/ml after 1.0 g administration and 2.0-27.0 micrograms/ml after 2.0 g administration. According to the above results, it is possible to successfully prevent or treat @entity281 by twice a day administration of @entity8353 at 1.0-2.0 g/dose. Clinically, @entity8353 was effective in the treatment of @entity281 and the prophylaxis of intrauterine @entity281 without any side effect. Moreover, newborn @entity1 delivered from mothers receiving @entity8353 treatment did not have any abnormalities in laboratory test. The penetration of @entity8353 into mother's milk was low, thus the transfer of @entity8353 from milk to newborn @entity1 should be low. The above results demonstrated that @entity8353 is a clinically useful antibiotic for the prophylaxis and the treatment of @entity281 .
